GLP-1 Agonists Do Not Increase Cancer Risk
GLP-1 agonists, including Ozempic, have become highly effective treatments for diabetes, obesity, insulin resistance, and other conditions primarily driven by insulin resistance. Yet, amidst their growing popularity, concerns have arisen about the potential long-term risks associated with their use, particularly the fear of thyroid and pancreatic cancers. However, recent studies have come forward to dispel…